Boehringer expands neurology activitiesBoehringer Ingelheim has expanded its 2014 R&D collaboration with the BioMed X Innovation Center (Heidelberg, Germany) to find new treatment approaches for early intervention of psychiatric dise … more ➔
New target for lung fibrosis discoveredCanadian and Finnish researchers have demonstrated that long immune cell contact to lung tissue turns tissue repair into fibrosis. more ➔
Valneva inks $59m JE vaccine supply contra...French vaccine specialist Valneva SE has inked a supply contract with the US Department of Defense for IXIARO its Japanese encephalitis (JE). more ➔
VTT turn waste into biofuels and chemicalsResearchers at VTT Technical Research Centre of Finland Ltd have presented a new gasification-based technique to turn forest industry byproducts into transport fuels and chemicals. more ➔
Tissue specific tumour transition needs fe...German researchers have modeled when cellular alterations inevitably lead to the development of cancer. The transition is tissue-specific and needs only a few cells. more ➔
Drug dissociates metastasis precursors in...A team of Swiss researchers has identified Na+/K+-ATPase blockers as candidate drugs capable to prevent formation of metastases. In blood, the repurposed drugs identified in a screening dissociated … more ➔
Policymakers take no action after ECJ muta...In summer the European Court of Justice (ECJ) ruled that crops created by biological mutagenesis techniques fall under EU GMO legislation. Germanys government and the European Parliament see no need … more ➔
Sandoz antiinfectives partner Ares Genet...Just in mid-December, antibiotic resistance detection expert Ares Genetics (Vienna, Austria) inked an agreement with Sandoz to use its pathogenome database and bio-IT know-how to develop repurposed … more ➔
AI provides face read-out of genetic disea...Experts in artificial intelligence (AI) have created another problem for bioethicists and data protection specialists: their algorithm has learned to identify people with rare genetic syndromes from … more ➔
Sanofi ends immuno-oncology discovery with...Sanofi and Regeneron announced they have "restructured" their US$2,17bn immunoncology collaboration. While the companies will continue co-marketing of the FDA approved (2018) PD1 blocker cemiplimab … more ➔
